The Korean Journal of Medicine

  • 제84권1호
  • /
  • Pages.62-70
  • /
  • 2013
  • /
  • 1738-9364(pISSN)
  • /
  • 2289-0769(eISSN)
대한내과학회 (The Korean Association of Internal Medicine)
권호 표지
DOI QR코드

DOI QR Code

혈전용해 치료를 시행한 광범위 및 아광범위 폐색전증 환자의 단기 사망률

Short-Term Mortality in Patients with Massive and Submassive Pulmonary Embolism Receiving Thrombolytic Therapy

  • 조윤주 (순천향대학교 의과대학 호흡기-알레르기내과) ;
  • 구소미 (순천향대학교 의과대학 호흡기-알레르기내과) ;
  • 방덕원 (순천향대학교 의과대학 순환기내과) ;
  • 김기업 (순천향대학교 의과대학 호흡기-알레르기내과) ;
  • 어수택 (순천향대학교 의과대학 호흡기-알레르기내과) ;
  • 김양기 (순천향대학교 의과대학 호흡기-알레르기내과)
  • Cho, Yun-Ju (Department of Respiratory and Allergy Medicine, Soonchunhyang University College of Medicine) ;
  • Koo, So-My (Department of Respiratory and Allergy Medicine, Soonchunhyang University College of Medicine) ;
  • Bang, Duk Won (Department of Cardiology Medicine, Soonchunhyang University College of Medicine) ;
  • Kim, Ki-Up (Department of Respiratory and Allergy Medicine, Soonchunhyang University College of Medicine) ;
  • Uh, Soo-Taek (Department of Respiratory and Allergy Medicine, Soonchunhyang University College of Medicine) ;
  • Kim, Yang-Ki (Department of Respiratory and Allergy Medicine, Soonchunhyang University College of Medicine)
  • 발행 : 2013.01.01
⟨ 이전 논문 다음 논문 ⟩

초록

목적: 혈전용해 치료에도 불구하고 광범위 및 아광범위 폐색전증의 사망률은 여전히 높다. 혈전용해치료는 광범위 폐색전증에서 생명을 구할 치료로 여겨지지만 진단 당시 저혈압이 없는 경우 저혈압으로 진행될 수 있는 고위험 환자에서만 선택적으로 적용되고 있다. 국내에서는 이와 관련된 소수의 문헌만이 있는 상태로 이에 혈전용해 치료를 시행한 광범위 및 아광범위 폐색전증 환자들의 단기 사망률에 대해 알아보고자 하였다. 방법: 2004년 1월 1일부터 2011년 7월 30일까지 91개월 동안 순천향대학교 서울병원에서 흉부 컴퓨터촬영을 통해 진단 후 혈전용해제가 투여된 광범위 및 아광범위 폐색전증 환자들을 대상으로 후향적 의무기록 조사를 하였다. 일차 결과는 치료 30일 이내의 사망으로 하였으며 이차 결과는 30일 이내의 주요출혈, 90일 이내의 사망, 90일 이내의 정맥혈전증의 재발로 하였다. 결과: 폐색전증 환자 중 혈전용해제를 투여 받은 환자는 21명으로 광범위 폐색전증 9명, 아광범위 폐색전증 12명이었다. 30일 이내 사망은 5명(24%)으로 광범위 폐색전증 환자 9명 중 4명(44%), 아광범위 폐색전증 환자 12명 중 1명(8%)으로 광범위 폐색전증에서 30일 사망률이 유의하게 높았다(p = 0.010). 혈전용해제 투여 후 30일 사망률과 90일 사망률은 동일하였다. 추정 사망원인은 5명 중 4명(80%)에서 우심실 부전으로 인한 순환기 허탈이었고 1명(20%)은 치명적 출혈로 인한 사망이었다. 혈전용해제 치료부터 사망까지의 시간은 1일(중간값, 0-13일)이었다. 주요출혈은 총 21명 중 3명(14%)에서 발생하였고 이 중 1명 (5%)은 출혈로 인한 사망으로 추정되었다. 90일 이내 정맥혈전증의 재발은 없었다. 결론: 혈전용해치료를 시행받은 환자 중 광범위 폐색전증 환자의 30일 사망률은 아광범위 폐색전증 환자보다 높았다.

Background/Aims: The mortality rate following massive and submassive pulmonary embolism (PE) remains high despite thrombolytic therapy. Although thrombolytic therapy is considered a life-saving intervention in massive PE, it is only selectively indicated in patients without hypotension who are at high risk of developing hypotension. Little is known about its clinical outcome in Korea. Methods: We retrospectively reviewed the records of patients given thrombolytics for massive and submassive PE objectively confirmed with chest computed tomography at Soon Chun Hyang University Hospital, Seoul, Korea, from 1 January 2004 to 1 August 2011. The primary outcome of this study was 30-day mortality. Secondary outcomes were the incidence of major bleeding at 30 days, mortality at 90 days, and recurrent venous thromboembolism (VTE) at 90 days. Results: Thrombolytic therapy was performed in 21 patients: nine with massive and 12 with submassive PE. The overall 30-day mortality rate was 24% (5/21). The mortality rate in patients with massive PE was higher than that in patients with submassive PE (44% vs. 8%, respectively; p = 0.010). Mortality rates at 90 and 30 days were identical. The estimated causes of death were right ventricular failure in four patients and fatal bleeding in one patient. The median time to death from thrombolysis was 1 day (0-13 days). Major bleeding episodes occurred in three patients (14%), including fatal bleeding in one patient. There was no recurrent VTE at 90 days. Conclusions: Patients who underwent thrombolytic therapy for massive PE showed a higher 30-day mortality compared with patients with submassive PE.

키워드

참고문헌

  1. Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141(2 Suppl):e419S-e494S. https://doi.org/10.1378/chest.11-2301
  2. Kasper W, Konstantinides S, Geibel A, et al. Management strategies and determinants of outcome in acute major pulmonary embolism: results of a multicenter registry. J Am Coll Cardiol 1997;30:1165-1171. https://doi.org/10.1016/S0735-1097(97)00319-7
  3. Goldhaber SZ, Visani L, De Rosa M. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet 1999;353:1386-1389. https://doi.org/10.1016/S0140-6736(98)07534-5
  4. Kucher N, Rossi E, De Rosa M, Goldhaber SZ. Massive pulmonary embolism. Circulation 2006;113:577-582. https://doi.org/10.1161/CIRCULATIONAHA.105.592592
  5. Kucher N, Rossi E, De Rosa M, Goldhaber SZ. Prognostic role of echocardiography among patients with acute pulmonary embolism and a systolic arterial pressure of 90 mm Hg or higher. Arch Intern Med 2005;165:1777-1781. https://doi.org/10.1001/archinte.165.15.1777
  6. Sanchez O, Trinquart L, Colombet I, et al. Prognostic value of right ventricular dysfunction in patients with haemodynamically stable pulmonary embolism: a systematic review. Eur Heart J 2008;29:1569-1577. https://doi.org/10.1093/eurheartj/ehn208
  7. Thabut G, Thabut D, Myers RP, et al. Thrombolytic therapy of pulmonary embolism: a meta-analysis. J Am Coll Cardiol 2002;40:1660-1667. https://doi.org/10.1016/S0735-1097(02)02381-1
  8. Agnelli G, Becattini C, Kirschstein T. Thrombolysis vs heparin in the treatment of pulmonary embolism: a clinical outcome-based meta-analysis. Arch Intern Med 2002;162:2537-2541. https://doi.org/10.1001/archinte.162.22.2537
  9. Han SY, Song JK, Lee SD, et al. Comparison of effect between thrombolysis and anticoagulation in major pulmonary thromboembolism. Tuberc Respir Dis 2005;59:487-496. https://doi.org/10.4046/trd.2005.59.5.487
  10. Yoo JW, Kim W, Choi CM, et al. The therapeutic efficacy and the bleeding complications of urokinase and alteplase in patients with massive pulmonary thromboembolism. Tuberc Respir Dis 2009;66:6-12. https://doi.org/10.4046/trd.2009.66.1.6
  11. Jaff MR, McMurtry MS, Archer SL, et al. Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a scientific statement from the American Heart Association. Circulation 2011;123:1788-1830. https://doi.org/10.1161/CIR.0b013e318214914f
  12. Buller HR, Davidson BL, Decousus H, et al. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med 2003;349:1695-1702. https://doi.org/10.1056/NEJMoa035451
  13. Buller HR, Davidson BL, Decousus H, et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med 2004;140:867-873. https://doi.org/10.7326/0003-4819-140-11-200406010-00007
  14. Heit JA. The epidemiology of venous thromboembolism in the community: implications for prevention and management. J Thromb Thrombolysis 2006;21:23-29. https://doi.org/10.1007/s11239-006-5572-y
  15. Wan S, Quinlan DJ, Agnelli G, Eikelboom JW. Thrombolysis compared with heparin for the initial treatment of pulmonary embolism: a meta-analysis of the randomized controlled trials. Circulation 2004;110:744-749. https://doi.org/10.1161/01.CIR.0000137826.09715.9C
  16. Jerjes-Sanchez C, Ramirez-Rivera A, de Lourdes Garcia M, et al. Streptokinase and heparin versus heparin alone in massive pulmonary embolism: a randomized controlled trial. J Thromb Thrombolysis 1995;2:227-229. https://doi.org/10.1007/BF01062714
  17. Konstantinides S, Geibel A, Heusel G, Heinrich F, Kasper W; Management Strategies and Prognosis of Pulmonary Embolism-3 Trial Investigators. Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism. N Engl J Med 2002;347:1143-1150. https://doi.org/10.1056/NEJMoa021274
  18. Kline JA, Steuerwald MT, Marchick MR, Hernandez-Nino J, Rose GA. Prospective evaluation of right ventricular function and functional status 6 months after acute submassive pulmonary embolism: frequency of persistent or subsequent elevation in estimated pulmonary artery pressure. Chest 2009;136:1202-1210. https://doi.org/10.1378/chest.08-2988
  19. Fasullo S, Scalzo S, Maringhini G, et al. Six-month echocardiographic study in patients with submassive pulmonary embolism and right ventricle dysfunction: comparison of thrombolysis with heparin. Am J Med Sci 2011;341:33-39. https://doi.org/10.1097/MAJ.0b013e3181f1fc3e
  20. Steering Committee. Single-bolus tenecteplase plus heparin compared with heparin alone for normotensive patients with acute pulmonary embolism who have evidence of right ventricular dysfunction and myocardial injury: rationale and design of the Pulmonary Embolism Thrombolysis (PEITHO) trial. Am Heart J 2012;163:33-38. https://doi.org/10.1016/j.ahj.2011.10.003
  21. Fiumara K, Kucher N, Fanikos J, Goldhaber SZ. Predictors of major hemorrhage following fibrinolysis for acute pulmonary embolism. Am J Cardiol 2006;97:127-129. https://doi.org/10.1016/j.amjcard.2005.07.117
  22. Meyer G, Gisselbrecht M, Diehl JL, Journois D, Sors H. Incidence and predictors of major hemorrhagic complications from thrombolytic therapy in patients with massive pulmonary embolism. Am J Med 1998;105:472-477. https://doi.org/10.1016/S0002-9343(98)00355-6
  23. Kanter DS, Mikkola KM, Patel SR, Parker JA, Goldhaber SZ. Thrombolytic therapy for pulmonary embolism: frequency of intracranial hemorrhage and associated risk factors. Chest 1997;111:1241-1245. https://doi.org/10.1378/chest.111.5.1241
  24. Kreit JW. The impact of right ventricular dysfunction on the prognosis and therapy of normotensive patients with pulmonary embolism. Chest 2004;125:1539-1545. https://doi.org/10.1378/chest.125.4.1539
  25. Schoepf UJ, Kucher N, Kipfmueller F, Quiroz R, Costello P, Goldhaber SZ. Right ventricular enlargement on chest computed tomography: a predictor of early death in acute pulmonary embolism. Circulation 2004;110:3276-3280. https://doi.org/10.1161/01.CIR.0000147612.59751.4C
  26. Becattini C, Vedovati MC, Agnelli G. Prognostic value of troponins in acute pulmonary embolism: a meta-analysis. Circulation 2007;116:427-433. https://doi.org/10.1161/CIRCULATIONAHA.106.680421
  27. Cavallazzi R, Nair A, Vasu T, Marik PE. Natriuretic peptides in acute pulmonary embolism: a systematic review. Intensive Care Med 2008;34:2147-2156. https://doi.org/10.1007/s00134-008-1214-5
  28. Kucher N, Goldhaber SZ. Cardiac biomarkers for risk stratification of patients with acute pulmonary embolism. Circulation 2003;108:2191-2194. https://doi.org/10.1161/01.CIR.0000100687.99687.CE
  29. Donze J, Le Gal G, Fine MJ, et al. Prospective validation of the Pulmonary Embolism Severity Index: a clinical prognostic model for pulmonary embolism. Thromb Haemost 2008;100:943-948. https://doi.org/10.1160/TH08-05-0285

피인용 문헌

  1. Thrombolysis in Pulmonary Embolism vol.84, pp.1, 2013, https://doi.org/10.3904/kjm.2013.84.1.46
  2. Acute Pulmonary Embolism and 1-Year Outcome: An Epidemiological Study in East of Iran, 2011-2016 vol.17, pp.1, 2013, https://doi.org/10.5812/modernc.95226